LCM™ for Drug Development

Highlights:

  • Predicate observational studies led to accelerated R&D For Phase 1 trials with TimepointDx LCM™ implementation, enabling faster and more efficient biomarker data inclusive of genomics, transcriptomics and proteomics.
  • Faster hypothesis generation was enabled to determine preclinical and discovery screening efficiency for putative therapeutic assets.
  • Mechanism of action (MOA) studies were accelerated via implementation of TimepointDx LCM™, both in observational and open-label extension studies.
  • For next-generation therapeutic asset planning, TimepointDx LCM™ was implemented directly into Phase 1 and 2 programs whereby OLE studies introduced TimepointDx LCM™ as exploratory biomarker endpoints.
  • Ongoing randomized clinical trials included TimepointDx LCM™ as exploratory biomarkers to generate and facilitate translational biomarker discovery for potential asset development.
  • TimepointDx LCM™ enabled patient-specific targeted hypothesis generation for precision medicine efforts.

See White Paper for Details.

Want the white paper? Contact us below!